Letter from J.W. Stone to James B. Finley

Rev. John W. Stone writes to his Presiding Elder, James B. Finley, from his new appointment in Newark. Stone reports that he sometimes feels discouraged about the backwardness of Newark church members, but conditions are slowly improving. He expresses gratitude to Finley for attending a quarterly meeting. Finley\u27s labors during that meeting will be long remembered. Stone needs Finley\u27s help to settle a problem from his previous appointment -- Putnam. It appears that he did not receive pay that was owed to him from the stewards. The stewards are arguing that rent was provided in lieu of pay. Stone is adamant that this is not the arrangement he had with the stewards. Abstract Number - 522https://digitalcommons.owu.edu/finley-letters/1819/thumbnail.jp

Letter from J.W. Stone to James B. Finley

Rev. J.W. Stone has completed the second year of his appointment to Newark. He will be leaving the dear people of Newark in a few days, and is feeling great sadness about it. I have become more strongly attached to the people, and they to me. He shares personal news concerning his family. Abstract Number - 297https://digitalcommons.owu.edu/finley-letters/1294/thumbnail.jp

Letter from J.W. Stone to James B. Finley

Rev. Stone encloses $2.12 collected by the members of Rushville Station as their contribution towards traveling expenses of Ohio delegates to General Conference. It is coming late because Stone suffered a serious stomach hemorrhage which nearly killed him. Folks are very anxious to learn the result of the property division vote. Stone hopes the Lord will influence the vote so as to promote His glory. Abstract Number - 378https://digitalcommons.owu.edu/finley-letters/1576/thumbnail.jp

Letter from J.W. Stone to James B. Finley

Rev. Stone is writing to the Presiding Elder of the Zanesville District, James B. Finley, concerning conditions at the Newark appointment. The congregation is large and class meetings are well attended. The $5.00 quarterage due Finley from the Newark congregation will be forwarded once it is raised. There has been an attempted suicide in town. Stone informs Finley that his trunk is completed and ready to be sent. Abstract Number - 254https://digitalcommons.owu.edu/finley-letters/1252/thumbnail.jp

Minimization via duality

We show how to use duality theory to construct minimized versions of a wide class of automata. We work out three cases in detail: (a variant of) ordinary automata, weighted automata and probabilistic automata. The basic idea is that instead of constructing a maximal quotient we go to the dual and look for a minimal subalgebra and then return to the original category. Duality ensures that the minimal subobject becomes the maximally quotiented object

Building Solar Capacity in Maine: The Greater Bangor Solarize Case Study

Despite being a mature technology with significantly decreasing costs over the last decade and various financial incentives available periodically, solar photovoltaic energy systems currently generate approximately 1 percent of Maine’s electricity. There have been eight Solarize campaigns in Maine, which aimed to increase residential- and commercial-scale solar adoption through group purchasing. In 2017, the Greater Bangor Solarize campaign increased the number of residential solar installations by 63 percent and solar power capacity by 52 percent in the participating towns compared to the previous seven years. We surveyed the Greater Bangor Solarize participants to better understand the motivations, concerns, and barriers to residential solar adoption in central Maine. We find a significant demographic divide exists between the Solarize participants and the general Maine population. We also observe that environmental stewardship and energy security are the primary motivations for considering solar and that overall cost remains the primary concern

Molino de bolas vibratorio

No disponibl

Nuclear energy density functional from chiral two- and three-nucleon interactions

An improved density-matrix expansion is used to calculate the nuclear energy density functional from chiral two- and three-nucleon interactions. The two-body interaction comprises long-range one- and two-pion exchange contributions and a set of contact terms contributing up to fourth power in momenta. In addition we employ the leading order chiral three-nucleon interaction with its parameters $c_E, c_D$ and $c_{1,3,4}$ fixed in calculations of nuclear few-body systems. With this input the nuclear energy density functional is derived to first order in the two- and three-nucleon interaction. We find that the strength functions $F_\nabla(\rho)$ and $F_{so}(\rho)$ of the surface and spin-orbit terms compare in the relevant density range reasonably with results of phenomenological Skyrme forces. However, an improved description requires (at least) the treatment of the two-body interaction to second order. This observation is in line with the deficiencies in the nuclear matter equation of state $\bar E(\rho)$ that remain in the Hartree-Fock approximation with low-momentum two- and three-nucleon interactions.Comment: 16 pages, 12 figures, submitted to Eur. Phys. J.

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus metronidazole compared with meropenem in patients with complicated intra-abdominal infection (cIAI) in Asian countries. Subjects aged 18–90 years and hospitalised with cIAI requiring surgical intervention were randomised 1:1 to receive every 8 h either: ceftazidime/avibactam (2000/500 mg, 2-h infusion) followed by metronidazole (500 mg, 60-min infusion); or meropenem (1000 mg, 30-min infusion). Non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was concluded if the lower limit of the 95% confidence interval (CI) for the between-group difference in clinical cure rate was greater than −12.5% at the test-of-cure (TOC) visit (28–35 days after randomisation) in the clinically evaluable (CE) population. Safety was also evaluated. Of 441 subjects randomised, 432 received at least one dose of study medication (ceftazidime/avibactam plus metronidazole, n = 215; meropenem, n = 217). In the CE population at the TOC visit, non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was demonstrated, with clinical cure reported for 93.8% (166/177) and 94.0% (173/184) of subjects, respectively (between-group difference, −0.2, 95% CI −5.53 to 4.97). The clinical cure rate with ceftazidime/avibactam plus metronidazole was comparable in subjects with ceftazidime-non-susceptible and ceftazidime-susceptible isolates (95.7% vs. 92.1%, respectively). Adverse events were similar between the study groups. Ceftazidime/avibactam plus metronidazole was non-inferior to meropenem in the treatment of cIAIs in Asian populations and was effective against ceftazidime-non-susceptible pathogens. No new safety concerns were identified